Skip to Content

Notice

Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Cancellation

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration is announcing the cancellation of a public workshop entitled “Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients” that was previously scheduled for August 8, 2019, from 8:30 a.m. to 4:30 p.m. This public workshop was announced in the Federal Register of May 2, 2019. The meeting has been cancelled due to unforeseen changes in the adenovirus drug development landscape.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Lori Benner and/or Jessica Barnes, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6221, Silver Spring, MD 20993-0002, 301-796-1300, about this public workshop, which was announced in the Federal Register of May 2, 2019 (84 FR 18848).

Start Signature

Dated: July 8, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

End Signature End Further Info End Preamble

[FR Doc. 2019-14887 Filed 7-11-19; 8:45 am]

BILLING CODE 4164-01-P